louisiana semaglutide diarrhea class action Lawsuit filed against makers of Ozempic, Mounjaro over claims of 'gastrointestinal side effects' Ozempic, Mounjaro cause gastrointestinal issues,

A thorough risk-benefit analysis supports the medications long-term value, with weight loss success rates showing 83% of users achieving at least 5% reduction in body weight

Brokers that provide early IPO access to individuals will enforce some qualifications, such as a minimum asset balance with the firm

Ritonavir inhibits the CYP3A-mediated metabolism of nirmatrelvir, resulting in increased plasma concentrations of nirmatrelvir

The argument: if the medication enables weight loss that translates to faster race times, it is performance-enhancing regardless of whether that was the primary intent

In SURPASS-4, Mounjaro lowered patient weight by 14 pounds (5 mg), 20 pounds (10 mg), and 23 pounds (15 mg) compared to a gain of 4 pounds with insulin glargine

While these findings should be interpreted with appropriate cautionthe study included only individuals with obesity (BMI 30 kg/m), and larger, more diverse trials are neededthey raise an important question